Bill Anderson, Bayer CEO (Dia Dipasupil/Getty Images)

Bay­er not eye­ing new deals to ad­dress Xarel­to sales ero­sion

Bay­er re­it­er­at­ed its plans to ride out the gener­ic-dri­ven sales de­cline of its throm­bo­sis drug Xarel­to, as the com­pa­ny’s shares plum­met­ed to a record low …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.